Rosulin (rosuvastatin calcium): Uses, Dosage & Side Effects

What it's for (Indications)

Rosuvastatin calcium, marketed under various brand names such as Roviros, is indicated as an adjunct to diet for the treatment of primary hyperlipidemia (Type IIa) and mixed dyslipidemia (Type IIb) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
It is also indicated for reducing the risk of major cardiovascular events, including myocardial infarction, stroke, and arterial revascularization procedures, in adults without clinically evident coronary heart disease but with multiple risk factors.
Furthermore, rosuvastatin is used in patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia), homozygous familial hypercholesterolemia (HoFH), and to slow the progression of atherosclerosis as part of a comprehensive treatment strategy to reduce TC and LDL-C levels.

Dosage Information

Type	Guideline
Standard	The dosage of rosuvastatin calcium should be individualized based on the patient's lipid levels, goals of therapy, and response. The recommended starting dose is typically 10 mg or 20 mg once daily. For patients requiring less aggressive LDL-C reduction or with predisposing factors for myopathy, a 5 mg starting dose may be considered. The maximum recommended dose is 40 mg once daily. Dosage adjustments should be made at intervals of 2 to 4 weeks if necessary, with regular monitoring of lipid profiles. For patients with severe renal impairment (CrCl < 30 mL/min/1.73 m²), the starting dose should be 5 mg once daily, and the 40 mg dose is contraindicated. In Asian patients, a starting dose of 5 mg once daily is recommended due to higher systemic exposure. Rosuvastatin can be administered as a single dose at any time of day, with or without food. Compliance with dietary modifications remains crucial throughout treatment.

Type

Guideline

Standard

The dosage of rosuvastatin calcium should be individualized based on the patient's lipid levels, goals of therapy, and response. The recommended starting dose is typically 10 mg or 20 mg once daily. For patients requiring less aggressive LDL-C reduction or with predisposing factors for myopathy, a 5 mg starting dose may be considered. The maximum recommended dose is 40 mg once daily. Dosage adjustments should be made at intervals of 2 to 4 weeks if necessary, with regular monitoring of lipid profiles. For patients with severe renal impairment (CrCl < 30 mL/min/1.73 m²), the starting dose should be 5 mg once daily, and the 40 mg dose is contraindicated. In Asian patients, a starting dose of 5 mg once daily is recommended due to higher systemic exposure. Rosuvastatin can be administered as a single dose at any time of day, with or without food. Compliance with dietary modifications remains crucial throughout treatment.

Safety & Warnings

Common Side Effects

Commonly reported side effects of rosuvastatin include headache, myalgia (muscle pain), asthenia (weakness or lack of energy), nausea, constipation, abdominal pain, and nasopharyngitis.
While generally well-tolerated, more serious but rare adverse events can occur.
These include myopathy and rhabdomyolysis, characterized by severe muscle pain, tenderness, or weakness, often accompanied by elevated creatine kinase (CK) levels, which can lead to acute renal failure.
Patients should be advised to report any unexplained muscle symptoms promptly.
Liver enzyme abnormalities, including persistent elevations of serum transaminases, have been observed and warrant monitoring of liver function tests.
Other reported rare side effects include new-onset diabetes mellitus, interstitial lung disease (presenting as dyspnea, non-productive cough, and constitutional symptoms), and cognitive impairment (e.
g.
, memory loss, confusion), which are generally reversible upon discontinuation of the statin.
Hypersensitivity reactions, including rash, pruritus, and urticaria, may also occur.

Serious Warnings

Black Box Warning: Rosuvastatin does not carry a specific FDA Black Box Warning. However, serious warnings warranting careful consideration are associated with its use. These include the potential for myopathy and rhabdomyolysis, characterized by severe muscle pain, weakness, and elevated creatine kinase (CK) levels, which can lead to acute renal failure. This risk is heightened with higher doses, concomitant use of certain medications (e.g., cyclosporine, gemfibrozil, certain antivirals), advanced age, renal impairment, and untreated hypothyroidism. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness. Additionally, liver enzyme abnormalities, including persistent elevations of serum transaminases, have been reported; liver function tests should be performed prior to and periodically during treatment. Rosuvastatin is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases. The drug is also contraindicated during pregnancy and breastfeeding due to potential fetal harm, as cholesterol is essential for fetal development.
Rosuvastatin calcium carries several important warnings that necessitate careful patient selection and monitoring.
The most significant concern is the potential for myopathy and rhabdomyolysis, a severe form of muscle breakdown that can lead to acute renal failure.
The risk of myopathy is dose-dependent and increased by concomitant use of certain medications (e.
g.
, cyclosporine, gemfibrozil, atazanavir/ritonavir, lopinavir/ritonavir, colchicine, niacin), advanced age, hypothyroidism, and renal impairment.
Patients should be counseled to report any unexplained muscle pain, tenderness, or weakness.
Baseline and periodic monitoring of liver function tests is crucial, as persistent elevations in serum transaminases can occur, indicating potential hepatotoxicity.
Rosuvastatin should be discontinued if transaminase levels persist at >3 times the upper limit of normal or if symptoms suggestive of liver injury develop.
A slight increase in glycated hemoglobin (HbA1c) and fasting blood glucose levels has been reported with statin therapy, potentially leading to new-onset diabetes mellitus in some individuals.
Interstitial lung disease has been rarely reported with statins and requires discontinuation if suspected.
Renal impairment necessitates dose adjustments due to increased exposure to rosuvastatin.

How it Works (Mechanism of Action)

Rosuvastatin calcium is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the rate-limiting step in cholesterol biosynthesis, specifically the conversion of HMG-CoA to mevalonate. By inhibiting HMG-CoA reductase, rosuvastatin effectively reduces the synthesis of cholesterol in the liver. This reduction in hepatic cholesterol leads to an upregulation of low-density lipoprotein (LDL) receptors on the surface of hepatocytes. The increased number of LDL receptors enhances the uptake and catabolism of circulating LDL-C from the bloodstream. Consequently, plasma concentrations of LDL-C are significantly lowered. Rosuvastatin also decreases very low-density lipoprotein (VLDL) production and triglyceride levels, while modestly increasing high-density lipoprotein cholesterol (HDL-C), thus improving the overall lipid profile and contributing to the prevention of atherosclerotic cardiovascular disease.